Compare ASX & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASX | ONC |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | Taiwan | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8B | 34.8B |
| IPO Year | 1995 | N/A |
| Metric | ASX | ONC |
|---|---|---|
| Price | $15.55 | $311.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $369.50 |
| AVG Volume (30 Days) | ★ 6.1M | 269.5K |
| Earning Date | 02-12-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 6.31 | N/A |
| EPS | 0.25 | ★ 0.58 |
| Revenue | ★ $20,657,920,055.00 | $4,972,687,000.00 |
| Revenue This Year | $9.63 | $895.40 |
| Revenue Next Year | $13.98 | $22.04 |
| P/E Ratio | ★ $28.14 | $503.22 |
| Revenue Growth | 6.07 | ★ 50.43 |
| 52 Week Low | $6.94 | $172.67 |
| 52 Week High | $16.51 | $385.22 |
| Indicator | ASX | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 41.88 |
| Support Level | $14.72 | $306.61 |
| Resistance Level | $16.51 | $318.12 |
| Average True Range (ATR) | 0.31 | 8.43 |
| MACD | -0.08 | -0.78 |
| Stochastic Oscillator | 45.25 | 36.90 |
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, Packaging segment contribute the maximum revenue. The packaging segment involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufactures, and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.